Haemonetics is showing early signs of a turnaround, with Q1 FY2027 revenue up 5.6% YoY and gross margin expanding to 59.8%, the highest in recent quarters. However, the company's elevated leverage (D/E of 1.40) and persistent TTM revenue decline of 2.0% warrant caution.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $1.35+4.7% vs $1.29 | $358M+3.7% vs $345M |
Q3 2026 Aug 6, 2026 | $1.14+5.6% vs $1.08 | $339M+3.5% vs $328M |
Q2 2026 May 7, 2026 | $1.29+0.8% vs $1.28 | $346M+2.8% vs $337M |
Q1 2026 Feb 5, 2026 | $1.31+3.1% vs $1.27 | $339M+2.1% vs $332M |
Haemonetics NYSE: HAE raised its fiscal 2027 revenue growth outlook after reporting double-digit organic growth in its second quarter, but lowered its operating margin expansion forecast as it invests to support an expanded relationship with plasma collector CSL.
Haemonetics Corporation (HAE) Q2 2027 Earnings Call Transcript
Haemonetics (HAE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Haemonetics (HAE) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.3 per share. This compares to earnings of $1.27 per share a year ago.
Benchmark HAE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Haemonetics Corporation (HAE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $119.93 | $5.45B | 53.63 | -1.97% | 7.52% | 12.07% | — | |
| $150.87 | $6.68B | 20.46 | -34.61% | 13.61% | 9.74% | 0.89% | |
| $126.56 | $4.3B | 42.23 | 7.57% | 5.68% | 6.02% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $0.24 | $16.72M | -0.14 | 15.4% | -747.19% | -94.35% | — | |
| $25.79 | $13.32B | -18.55 | 5.72% | -6.23% | -11.67% | 2.63% |
Haemonetics Corporation (HAE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Haemonetics Corporation (HAE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 28, 2026·SEC
Jun 5, 2026·SEC
Get notified when HAE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Haemonetics Corporation (HAE) stock FAQ — growth, dividends, profitability & financials explained
Haemonetics Corporation (HAE) reported $1.38B in revenue over the trailing twelve months. Revenue was $1.33B in fiscal year 2026. That is 331% more than the $309.8M of fiscal year 1997.
Haemonetics Corporation (HAE) grew revenue by 4.1% over the trailing twelve months, compared with the twelve months before.
Yes. Haemonetics Corporation (HAE) earned $103.9M in net income over the trailing twelve months (a 7.5% net margin).
Haemonetics Corporation (HAE) had a return on equity (ROE) of 12.1% over the trailing twelve months. That is in line with the market's typical 10-15%.
Haemonetics Corporation (HAE) generated $303.8M in free cash flow over the trailing twelve months.
